Inactive Ingredient Search for Approved Drug Products
You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with View All
| Quarter | Inactive Ingredient | Route of Administration | Dosage Form | Maximum Potency per unit dose | Maximum Daily Exposure | Status | |
|---|---|---|---|---|---|---|---|
| Q3 2022 | ANHYDROUS LACTOSE | ORAL | TABLET, DELAYED RELEASE | 3250mg | Correction | ||
| Q4 2022 | ANHYDROUS LACTOSE | ORAL | TABLET, DELAYED RELEASE | 1083mg | Correction | ||
| Q3 2022 | CHERRY | ORAL | SOLUTION | 233mg | Correction | ||
| Q4 2022 | FLAVOR CHERRY FT-9496 | ORAL | SOLUTION | 200mg | Correction | ||
| Q4 2022 | HYDROXYPROPYL CELLULOSE (90000 WAMW) | BUCCAL | FILM, SOLUBLE | 292mg | Correction | ||
| Q4 2022 | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | BUCCAL | FILM, SOLUBLE | 292mg | Correction | ||
| Q3 2022 | HYPROMELLOSE | ORAL | POWDER, FOR SUSPENSION | 150.00 mg | Correction | ||
| Q4 2022 | HYPROMELLOSE | ORAL | POWDER, FOR SUSPENSION | 65.00 mg/ 5.00 ml | Correction | ||
| Q3 2022 | HYPROMELLOSE | ORAL | SOLUTION | 21.90 mg/ 5.00 ml | Correction | ||
| Q4 2022 | HYPROMELLOSE | ORAL | SOLUTION | 3.70 mg/ 1.00 ml | Correction | ||
| Q3 2022 | HYPROMELLOSE | ORAL | SUSPENSION | 1832mg | Correction | ||
| Q4 2022 | HYPROMELLOSE | ORAL | SUSPENSION | 305mg | Correction | ||
| Q3 2022 | HYPROMELLOSE ACETATE SUCCINATE | ORAL | CAPSULE | 89mg | Correction | ||
| Q4 2022 | HYPROMELLOSE ACETATE SUCCINATE, UNSPECIFIED | ORAL | CAPSULE | 89mg | Correction | ||
| Q3 2022 | HYPROMELLOSE ACETATE SUCCINATE | ORAL | CAPSULE, DELAYED RELEASE | 104mg | Correction | ||
| Q4 2022 | Hypromellose acetate succinate 12070923 (3 mPa.s) | ORAL | CAPSULE, DELAYED RELEASE | 104mg | Correction | ||
| Q3 2022 | HYPROMELLOSE ACETATE SUCCINATE | ORAL | CAPSULE, EXTENDED RELEASE | 67mg | Correction | ||
| Q4 2022 | HYPROMELLOSE ACETATE SUCCINATE, UNSPECIFIED | ORAL | CAPSULE, EXTENDED RELEASE | 67mg | Correction | ||
| Q3 2022 | HYPROMELLOSE ACETATE SUCCINATE | ORAL | GRANULE | 92mg | Correction | ||
| Q4 2022 | HYPROMELLOSE ACETATE SUCCINATE, UNSPECIFIED | ORAL | GRANULE | 92mg | Correction | ||
| Q3 2022 | HYPROMELLOSE ACETATE SUCCINATE | ORAL | TABLET | 4480mg | Correction | ||
| Q4 2022 | HYPROMELLOSE ACETATE SUCCINATE, UNSPECIFIED | ORAL | TABLET | 4480mg | Correction | ||
| Q3 2022 | HYPROMELLOSE ACETATE SUCCINATE | ORAL | TABLET, DELAYED RELEASE | 2040mg | Correction | ||
| Q4 2022 | HYPROMELLOSE ACETATE SUCCINATE, UNSPECIFIED | ORAL | TABLET, DELAYED RELEASE | 2040mg | Correction | ||
| Q3 2022 | HYPROMELLOSE ACETATE SUCCINATE | ORAL | TABLET, EXTENDED RELEASE | 29.00 mg | Correction | ||
| Q4 2022 | HYPROMELLOSE ACETATE SUCCINATE, UNSPECIFIED | ORAL | TABLET, EXTENDED RELEASE | 29.00 mg | Correction | ||
| Q3 2022 | HYPROMELLOSE ACETATE SUCCINATE 12070923 (3 MM2/S) | ORAL | TABLET, DELAYED RELEASE | 1800mg | Correction | ||
| Q4 2022 | HYPROMELLOSE ACETATE SUCCINATE 12070923 (3 MPA.S) | ORAL | TABLET, DELAYED RELEASE | 1800mg | Correction | ||
| Q3 2022 | HYPROMELLOSE ACETATE SUCCINATE 16070722 (3 MM2/S) | ORAL | CAPSULE, DELAYED RELEASE | 99mg | Correction | ||
| Q4 2022 | HYPROMELLOSE ACETATE SUCCINATE 16070722 (3 MPA.S) | ORAL | CAPSULE, DELAYED RELEASE | 99mg | Correction | ||
| Q3 2022 | MANNITOL | ORAL | POWDER | 4663mg | Correction | ||
| Q4 2022 | MANNITOL | ORAL | POWDER | 4352mg | Correction | ||
| Q3 2022 | NIACINAMIDE | TOPICAL | GEL | 25mg | Correction | ||
| Q4 2022 | NIACINAMIDE | TOPICAL | GEL | 1.25 %w/w | Correction | ||
| Q3 2022 | PEG-32 HYDROGENATED PALM GLYCERIDES | ORAL | CAPSULE, EXTENDED RELEASE | 8mg | Correction | ||
| Q4 2022 | STEAROYL POLYOXYL-32 GLYCERIDES | ORAL | CAPSULE, EXTENDED RELEASE | 8mg | Correction | ||
| Q3 2022 | PETROLATUM | OPHTHALMIC | OINTMENT | 97.00 %w/w | Correction | ||
| Q4 2022 | PETROLATUM | OPHTHALMIC | OINTMENT | 88.40 %w/w | Correction | ||
| Q3 2022 | PHENOXYETHANOL | TOPICAL | GEL | 14mg | Correction | ||
| Q4 2022 | PHENOXYETHANOL | TOPICAL | GEL | 0.70 %w/w | Correction | ||
| Q3 2022 | POLOXAMER 124 | TOPICAL | GEL | 6mg | Correction | ||
| Q4 2022 | POLOXAMER 124 | TOPICAL | GEL | 4mg | Correction | ||
| Q3 2022 | POLY(DL-LACTIC-CO-GLYCOLIC ACID), (50:50; 12000 MW) | ENDOSINUSIAL | IMPLANT | 1.35 mg | Correction | ||
| Q4 2022 | DL-LACTIDE AND GLYCOLIDE (50:50) COPOLYMER 12000 ACID | ENDOSINUSIAL | IMPLANT | 1.35 mg | Correction | ||
| Q3 2022 | POLY(DL-LACTIC-CO-GLYCOLIC ACID), (50:50; 12000 MW) | INTRAVITREAL | IMPLANT | 116.00 mg | Correction | ||
| Q4 2022 | DL-LACTIDE AND GLYCOLIDE (50:50) COPOLYMER 12000 ACID | INTRAVITREAL | IMPLANT | 116.00 mg | Correction | ||
| Q3 2022 | POLY(DL-LACTIC-CO-GLYCOLIC ACID), (50:50; 12000 MW) | INTRAVITREAL | INJECTION | 116.00 mg | Correction | ||
| Q4 2022 | DL-LACTIDE AND GLYCOLIDE (50:50) COPOLYMER 12000 ACID | INTRAVITREAL | INJECTION | 116.00 mg | Correction | ||
| Q3 2022 | POLY(DL-LACTIC-CO-GLYCOLIC ACID), (50:50; 12000 MW) | SUBCUTANEOUS | INJECTION, SOLUTION | 533.00 mg | Correction | ||
| Q4 2022 | DL-LACTIDE AND GLYCOLIDE (50:50) COPOLYMER 12000 ACID | SUBCUTANEOUS | INJECTION, SOLUTION | 533.00 mg | Correction | ||
| Q3 2022 | POLY(DL-LACTIC-CO-GLYCOLIC ACID), (50:50; 12000 MW) | SUBCUTANEOUS | INJECTION, SUSPENSION, EXTENDED RELEASE | 48mg | Correction | ||
| Q4 2022 | DL-LACTIDE AND GLYCOLIDE (50:50) COPOLYMER 63000 ACID | SUBCUTANEOUS | INJECTION, SUSPENSION, EXTENDED RELEASE | 37mg | Correction | ||
| Q3 2022 | POLY(DL-LACTIC-CO-GLYCOLIC ACID), (50:50; 63000 MW) | INTRAMUSCULAR | INJECTION | 60.70 mg | Correction | ||
| Q4 2022 | DL-LACTIDE AND GLYCOLIDE (50:50) COPOLYMER 63000 ACID | INTRAMUSCULAR | INJECTION | 60.70 mg | Correction | ||
| Q3 2022 | POLY(DL-LACTIC-CO-GLYCOLIC ACID), (50:50; 63000 MW) | SUBCUTANEOUS | IMPLANT | 16.20 mg | Correction | ||
| Q4 2022 | DL-LACTIDE AND GLYCOLIDE (50:50) COPOLYMER 63000 ACID | SUBCUTANEOUS | IMPLANT | 16mg | Correction | ||
| Q3 2022 | POLY(DL-LACTIC-CO-GLYCOLIC ACID), (75:25; 20000 MW) | INTRAMUSCULAR | INJECTION | 145mg | Correction | ||
| Q4 2022 | DL-LACTIDE AND GLYCOLIDE (75:25) COPOLYMER 20000 ACID | INTRAMUSCULAR | INJECTION | 145mg | Correction | ||
| Q3 2022 | POLYSORBATE 80 | RECTAL | SOLUTION | 840mg | Correction | ||
| Q4 2022 | POLYSORBATE 80 | RECTAL | SOLUTION | 315mg | Correction | ||
| Q3 2022 | POLYVINYL ALCOHOL | ORAL | TABLET, ORALLY DISINTEGRATING | 10mg | Correction | ||
| Q4 2022 | POLYVINYL ALCOHOL | ORAL | TABLET, ORALLY DISINTEGRATING | 6mg | Correction | ||
| Q3 2022 | PROPYLENE GLYCOL | ORAL | POWDER | 330mg | Correction | ||
| Q4 2022 | PROPYLENE GLYCOL | ORAL | POWDER | 55.00 mg | Correction | ||
| Q3 2022 | SODIUM ACETATE | INTRAVENOUS | INJECTION | 984mg | Correction | ||
| Q4 2022 | SODIUM ACETATE | INTRAVENOUS | INJECTION | 56mg | Correction | ||
| Q3 2022 | SODIUM N-(CARBONYL-METHOXYPOLYETHYLENE GLYCOL-2000)-DISTEAROYL-RAC-GLYCEROPHOSPHOETHANOLAMINE | INTRAVENOUS | INJECTION, SUSPENSION, LIPOSOMAL | 0.32 %w/v | Correction | ||
| Q4 2022 | SODIUM N-(CARBONYL-METHOXYPOLYETHYLENE GLYCOL 2000)-1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE | INTRAVENOUS | INJECTION, SUSPENSION, LIPOSOMAL | 0.32 %w/v | Correction | ||
| Q3 2022 | SORBITAN MONOOLEATE | TOPICAL | GEL | 6mg | Correction | ||
| Q4 2022 | SORBITAN MONOOLEATE | TOPICAL | GEL | 4mg | Correction | ||
| Q3 2022 | SORBITAN MONOSTEARATE | TOPICAL | CREAM, AUGMENTED | 2.00 %w/w | Correction | ||
| Q4 2022 | SORBITAN MONOSTEARATE | TOPICAL | CREAM, AUGMENTED | 0.75 %w/w | Correction | ||
| Q3 2022 | SORBITOL | ORAL | CAPSULE, LIQUID FILLED | 51mg | Correction | ||
| Q4 2022 | SORBITOL | ORAL | CAPSULE, LIQUID FILLED | 25mg | Correction | ||
| Q3 2022 | STARCH, CORN | BUCCAL | TABLET | 16.60 mg | Correction | ||
| Q4 2022 | STARCH 1500, PREGELATINIZED | BUCCAL | TABLET | 9mg | Correction | ||
| Q3 2022 | STARCH, CORN | ORAL | CAPSULE | 5785mg | Correction | ||
| Q4 2022 | STARCH 1500, PREGELATINIZED | ORAL | CAPSULE | 5785mg | Correction | ||
| Q3 2022 | STARCH, CORN | ORAL | CAPSULE, COATED, EXTENDED RELEASE | 19mg | Correction | ||
| Q4 2022 | STARCH 1500, PREGELATINIZED | ORAL | CAPSULE, COATED, EXTENDED RELEASE | 19mg | Correction | ||
| Q3 2022 | STARCH, CORN | ORAL | CAPSULE, DELAYED RELEASE | 216mg | Correction | ||
| Q4 2022 | STARCH 1500, PREGELATINIZED | ORAL | CAPSULE, DELAYED RELEASE | 216mg | Correction | ||
| Q3 2022 | STARCH, CORN | ORAL | CAPSULE, EXTENDED RELEASE | 194mg | Correction | ||
| Q4 2022 | STARCH 1500, PREGELATINIZED | ORAL | CAPSULE, EXTENDED RELEASE | 194mg | Correction | ||
| Q3 2022 | STARCH, CORN | ORAL | CONCENTRATE | NA | Correction | ||
| Q4 2022 | STARCH 1500, PREGELATINIZED | ORAL | CONCENTRATE | NA | Correction | ||
| Q3 2022 | STARCH, CORN | ORAL | DROPS | NA | Correction | ||
| Q4 2022 | STARCH 1500, PREGELATINIZED | ORAL | DROPS | NA | Correction | ||
| Q3 2022 | STARCH, CORN | ORAL | PASTILLE | NA | Correction | ||
| Q4 2022 | STARCH 1500, PREGELATINIZED | ORAL | PASTILLE | NA | Correction | ||
| Q3 2022 | STARCH, CORN | ORAL | POWDER, FOR SUSPENSION | 34mg | Correction | ||
| Q4 2022 | STARCH 1500, PREGELATINIZED | ORAL | POWDER, FOR SUSPENSION | 34mg | Correction | ||
| Q3 2022 | STARCH, CORN | ORAL | SUSPENSION | 900mg | Correction | ||
| Q4 2022 | STARCH 1500, PREGELATINIZED | ORAL | SUSPENSION | 900mg | Correction | ||
| Q3 2022 | STARCH, CORN | ORAL | SUSPENSION/ DROPS | 90mg | Correction | ||
| Q4 2022 | STARCH 1500, PREGELATINIZED | ORAL | SUSPENSION/ DROPS | 90mg | Correction | ||
| Q3 2022 | STARCH, CORN | ORAL | TABLET | 1116mg | Correction | ||
| Q4 2022 | STARCH 1500, PREGELATINIZED | ORAL | TABLET | 1116mg | Correction | ||
| Q3 2022 | STARCH, CORN | ORAL | TABLET, CHEWABLE | 180mg | Correction | ||
| Q4 2022 | STARCH 1500, PREGELATINIZED | ORAL | TABLET, CHEWABLE | 180mg | Correction | ||
| Q3 2022 | STARCH, CORN | ORAL | TABLET, COATED | 256mg | Correction | ||
| Q4 2022 | STARCH 1500, PREGELATINIZED | ORAL | TABLET, COATED | 256mg | Correction | ||
| Q3 2022 | STARCH, CORN | ORAL | TABLET, DELAYED RELEASE | 240mg | Correction | ||
| Q4 2022 | STARCH 1500, PREGELATINIZED | ORAL | TABLET, DELAYED RELEASE | 130mg | Correction | ||
| Q3 2022 | STARCH, CORN | ORAL | TABLET, EXTENDED RELEASE | 184mg | Correction | ||
| Q4 2022 | STARCH 1500, PREGELATINIZED | ORAL | TABLET, EXTENDED RELEASE | 184mg | Correction | ||
| Q3 2022 | STARCH, CORN | ORAL | TABLET, FILM COATED | 696mg | Correction | ||
| Q4 2022 | STARCH 1500, PREGELATINIZED | ORAL | TABLET, FILM COATED | 696mg | Correction | ||
| Q3 2022 | STARCH, CORN | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 149mg | Correction | ||
| Q4 2022 | STARCH 1500, PREGELATINIZED | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 149mg | Correction | ||
| Q3 2022 | STARCH, CORN | ORAL | TABLET, ORALLY DISINTEGRATING | 100mg | Correction | ||
| Q4 2022 | STARCH 1500, PREGELATINIZED | ORAL | TABLET, ORALLY DISINTEGRATING | 100mg | Correction | ||
| Q3 2022 | STARCH, CORN | ORAL | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE | 10mg | Correction | ||
| Q4 2022 | STARCH 1500, PREGELATINIZED | ORAL | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE | 21mg | Correction | ||
| Q3 2022 | STARCH, CORN | SUBLINGUAL | TABLET | 409mg | Correction | ||
| Q4 2022 | STARCH 1500, PREGELATINIZED | SUBLINGUAL | TABLET | 409mg | Correction | ||
| Q3 2022 | SUCRALOSE | NASAL | SPRAY, METERED | 358mg | Correction | ||
| Q4 2022 | SUCRALOSE | NASAL | SPRAY, METERED | 2mg | Correction | ||
| Q3 2022 | TOCOPHEROL | ORAL | CAPSULE | 4.00 mg | Correction | ||
| Q4 2022 | TOCOPHEROL | ORAL | CAPSULE | NA | Correction | ||
| Q3 2022 | TRISODIUM CITRATE DIHYDRATE | ORAL | SUSPENSION | 4950mg | Correction | ||
| Q4 2022 | TRISODIUM CITRATE DIHYDRATE | ORAL | SUSPENSION | 947mg | Correction | ||
| Q4 2022 | ADIPIC ACID | VAGINAL | TABLET | 57.00 mg | Deletion | ||
| Q4 2022 | ANHYDROUS CITRIC ACID | ORAL | LIQUID, EXTENDED RELEASE | 5.18 mg/ 1.00 ml | 62mg | Deletion | |
| Q4 2022 | ANHYDROUS TRISODIUM CITRATE | ORAL | LIQUID, EXTENDED RELEASE | 3.90 mg/ 1.00 ml | 47mg | Deletion | |
| Q4 2022 | CARBOMER HOMOPOLYMER | RECTAL | ENEMA | NA | Deletion | ||
| Q4 2022 | CELLULOSE ACETATE CA-398-10 | ORAL | TABLET | 20.93 mg | Deletion | ||
| Q4 2022 | COMPRESSIBLE SUGAR | ORAL | LIQUID, EXTENDED RELEASE | 145.50 mg/ 1.00 ml | 1746mg | Deletion | |
| Q4 2022 | CROSPOVIDONE | ORAL | TABLET, COATED PARTICLES | 130.00 mg | 1040mg | Deletion | |
| Q4 2022 | D&C YELLOW NO. 10 | ORAL | SUSPENSION/ DROPS | NA | Deletion | ||
| Q4 2022 | DISTEAROYLPHOSPHATIDYLCHOLINE, DL- | INTRAVENOUS | INJECTION | 0.68 %w/v | Deletion | ||
| Q4 2022 | ETHYLCELLULOSE (10 MPA.S) | ORAL | LIQUID, EXTENDED RELEASE | 4.17 mg/ 1.00 ml | 50mg | Deletion | |
| Q4 2022 | ETHYLCELLULOSE (20 MPA.S) | ORAL | POWDER | 298.50 mg | Deletion | ||
| Q3 2022 | FLAVOR GRAPE 61.13252 | ORAL | SYRUP | 2.00 mg/ 1.00 ml | 20mg | Deletion | |
| Q4 2022 | GLYCINE | ORAL | SUSPENSION/ DROPS | NA | Deletion | ||
| Q4 2022 | HYPROMELLOSE | VAGINAL | TABLET, FILM COATED | 54.21 mg | Deletion | ||
| Q4 2022 | HYPROMELLOSE 2208 (15000 MPA.S) | BUCCAL | TABLET, EXTENDED RELEASE | 17.25 mg | Deletion | ||
| Q4 2022 | HYPROMELLOSE ACETATE SUCCINATE 06081224 (3 MM2/S) | ORAL | CAPSULE, EXTENDED RELEASE | 56.55 mg | 57mg | Deletion | |
| Q4 2022 | HYPROMELLOSE ACETATE SUCCINATE 06081224 (3 MM2/S) | ORAL | TABLET, EXTENDED RELEASE | 9.92 mg | Deletion | ||
| Q4 2022 | ISOPROPYL PALMITATE | TOPICAL | CREAM, AUGMENTED | 4.00 %w/w | Deletion | ||
| Q4 2022 | LACTOSE MONOHYDRATE | VAGINAL | TABLET, FILM COATED | 17.90 mg | Deletion | ||
| Q4 2022 | MAGNESIUM SILICATE | ORAL | TABLET, COATED PARTICLES | 30.00 mg | 180mg | Deletion | |
| Q4 2022 | MAGNESIUM STEARATE | BUCCAL | TABLET, EXTENDED RELEASE | 0.58 mg | 1mg | Deletion | |
| Q4 2022 | MAGNESIUM STEARATE | ORAL | TABLET, COATED PARTICLES | 7.00 mg | 42mg | Deletion | |
| Q4 2022 | MAGNESIUM STEARATE | VAGINAL | TABLET, FILM COATED | 0.40 mg | Deletion | ||
| Q4 2022 | MEDIUM-CHAIN TRIGLYCERIDES | ORAL | CAPSULE, EXTENDED RELEASE | 3.08 mg | 5mg | Deletion | |
| Q4 2022 | METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | ORAL | TABLET, COATED PARTICLES | 27.90 mg | 167mg | Deletion | |
| Q4 2022 | MICROCRYSTALLINE CELLULOSE | BUCCAL | TABLET, EXTENDED RELEASE | 18.04 mg | Deletion | ||
| Q4 2022 | MICROCRYSTALLINE CELLULOSE | ORAL | TABLET, COATED PARTICLES | 283.60 mg | 2269mg | Deletion | |
| Q4 2022 | MILK PROTEIN CONCENTRATE | BUCCAL | TABLET, EXTENDED RELEASE | 23.00 mg | 23mg | Deletion | |
| Q4 2022 | OLEYL ALCOHOL | TOPICAL | CREAM, AUGMENTED | 2.00 %w/w | Deletion | ||
| Q4 2022 | OPACODE S-1-8106 BLACK | ORAL | TABLET, EXTENDED RELEASE | NA | Deletion | ||
| Q4 2022 | OPADRY YS-1-10533A | ORAL | TABLET | 8.16 mg | Deletion | ||
| Q4 2022 | OPADRY YS-1-10533A | ORAL | TABLET, EXTENDED RELEASE | 40.00 mg | 80mg | Deletion | |
| Q4 2022 | POLOXAMER 188 | ORAL | LIQUID, EXTENDED RELEASE | 0.50 mg/ 1.00 ml | 6mg | Deletion | |
| Q4 2022 | POLYESTER RAYON | TRANSDERMAL | SYSTEM | 96.50 mg | Deletion | ||
| Q4 2022 | POLYETHYLENE GLYCOL 6000 | VAGINAL | TABLET, FILM COATED | 0.06 mg | Deletion | ||
| Q4 2022 | POLYOXYL 20 CETOSTEARYL ETHER | TOPICAL | CREAM, AUGMENTED | 3.00 %w/w | Deletion | ||
| Q4 2022 | POLYVINYL ALCOHOL (108000 MW) | ORAL | TABLET | 38.27 mg | Deletion | ||
| Q4 2022 | POLYVINYL ALCOHOL (108000 MW) | ORAL | TABLET, EXTENDED RELEASE | 11.58 mg | 116mg | Deletion | |
| Q4 2022 | POVIDONE K30 | BUCCAL | TABLET, EXTENDED RELEASE | 0.50 mg | 1mg | Deletion | |
| Q4 2022 | POVIDONE K30 | ORAL | LIQUID, EXTENDED RELEASE | 1.03 mg/ 1.00 ml | 12mg | Deletion | |
| Q4 2022 | PROPYLENE GLYCOL | ORAL | TABLET, COATED PARTICLES | 4.20 mg | 34mg | Deletion | |
| Q4 2022 | SILICON DIOXIDE | BUCCAL | TABLET, EXTENDED RELEASE | 0.46 mg | Deletion | ||
| Q4 2022 | SILICON DIOXIDE | ORAL | LIQUID, EXTENDED RELEASE | 2.03 mg/ 1.00 ml | 24mg | Deletion | |
| Q4 2022 | SILICON DIOXIDE | ORAL | TABLET, COATED PARTICLES | 25.00 mg/ 5.00 ml | 200mg | Deletion | |
| Q4 2022 | SODIUM BENZOATE | ORAL | LIQUID, EXTENDED RELEASE | 2.00 mg/ 1.00 ml | 24mg | Deletion | |
| Q4 2022 | SODIUM BICARBONATE | VAGINAL | TABLET | 43.00 mg | Deletion | ||
| Q4 2022 | SODIUM LAURYL SULFATE | BUCCAL | TABLET, EXTENDED RELEASE | 5.18 mg | Deletion | ||
| Q3 2022 | SODIUM LAURYL SULFATE | VAGINAL | TABLET | 5.00 mg | Deletion | ||
| Q4 2022 | SODIUM PHOSPHATE, MONOBASIC | BUCCAL | FILM | 0.47 mg | Deletion | ||
| Q4 2022 | SODIUM POLYSTYRENE SULFONATE | ORAL | LIQUID, EXTENDED RELEASE | 14.90 mg/ 1.00 ml | 179mg | Deletion | |
| Q4 2022 | SODIUM POLYSTYRENE SULFONATE | ORAL | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE | 43.75 mg | 44mg | Deletion | |
| Q4 2022 | SODIUM STARCH GLYCOLATE TYPE A | ORAL | TABLET, COATED PARTICLES | 10.00 mg | 60mg | Deletion | |
| Q4 2022 | STARCH, CORN | ORAL | LIQUID, EXTENDED RELEASE | 9.38 mg/ 1.00 ml | 113mg | Deletion | |
| Q3 2022 | STARCH, CORN | VAGINAL | TABLET | 49 mg | 300mg | Deletion | |
| Q4 2022 | STARCH, CORN | VAGINAL | TABLET, FILM COATED | 8.00 mg | 8mg | Deletion | |
| Q4 2022 | SUCRALOSE | ORAL | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE | 6.00 mg | 6mg | Deletion | |
| Q4 2022 | SUCROSE | ORAL | LIQUID, EXTENDED RELEASE | 0.80 mg/ 1.00 ml | 10mg | Deletion | |
| Q4 2022 | TALC | ORAL | LIQUID, EXTENDED RELEASE | 3.83 mg/ 1.00 ml | 46mg | Deletion | |
| Q4 2022 | TALC | ORAL | TABLET, COATED PARTICLES | 6.50 mg | 39mg | Deletion | |
| Q4 2022 | TRIETHYL CITRATE | ORAL | LIQUID, EXTENDED RELEASE | 0.42 mg/ 1.00 ml | 5mg | Deletion | |
| Q4 2022 | XANTHAN GUM | ORAL | LIQUID, EXTENDED RELEASE | 4.17 mg/ 1.00 ml | 50mg | Deletion | |
| Q3 2022 | ADIPIC ACID | VAGINAL | INSERT | 57.00 mg | MDE Replacement | ||
| Q4 2022 | ADIPIC ACID | VAGINAL | INSERT | 171mg | MDE Replacement | ||
| Q3 2022 | AMMONIUM ACETATE | INTRAMUSCULAR | INJECTION | 0.80 %w/v | MDE Replacement | ||
| Q4 2022 | AMMONIUM ACETATE | INTRAMUSCULAR | INJECTION | 160mg | MDE Replacement | ||
| Q3 2022 | AMMONIUM ACETATE | INTRAVENOUS | INJECTION | 0.80 %w/v | MDE Replacement | ||
| Q4 2022 | AMMONIUM ACETATE | INTRAVENOUS | INJECTION | 160mg | MDE Replacement | ||
| Q3 2022 | AMMONIUM SULFATE | INTRAVENOUS | INJECTABLE, LIPOSOMAL | 0.20 %w/v | MDE Replacement | ||
| Q4 2022 | AMMONIUM SULFATE | INTRAVENOUS | INJECTABLE, LIPOSOMAL | 81mg | MDE Replacement | ||
| Q3 2022 | ANHYDROUS CITRIC ACID | INTRAVENOUS | INJECTION, SOLUTION | 0.53 %w/v | MDE Replacement | ||
| Q4 2022 | ANHYDROUS CITRIC ACID | INTRAVENOUS | INJECTION, SOLUTION | 540mg | MDE Replacement | ||
| Q3 2022 | ANHYDROUS CITRIC ACID | ORAL | SUSPENSION | 720.00 mg | MDE Replacement | ||
| Q4 2022 | ANHYDROUS CITRIC ACID | ORAL | SUSPENSION | 300mg | MDE Replacement | ||
| Q3 2022 | ANHYDROUS CITRIC ACID | ORAL | SUSPENSION/ DROPS | 2.50 mg/ 1.00 ml | MDE Replacement | ||
| Q4 2022 | ANHYDROUS CITRIC ACID | ORAL | SUSPENSION/ DROPS | 14mg | MDE Replacement | ||
| Q3 2022 | ASCORBIC ACID | TOPICAL | GEL | 0.30 %w/w | MDE Replacement | ||
| Q4 2022 | ASCORBIC ACID | TOPICAL | GEL | 3mg | MDE Replacement | ||
| Q3 2022 | BENZYL ALCOHOL | INTRAMUSCULAR | INJECTION, SUSPENSION | 0.92 %w/v | MDE Replacement | ||
| Q4 2022 | BENZYL ALCOHOL | INTRAMUSCULAR | INJECTION, SUSPENSION | 40mg | MDE Replacement | ||
| Q3 2022 | BENZYL ALCOHOL | SOFT TISSUE | INJECTION, SUSPENSION | 0.92 %w/v | MDE Replacement | ||
| Q4 2022 | BENZYL ALCOHOL | SOFT TISSUE | INJECTION, SUSPENSION | 40mg | MDE Replacement | ||
| Q3 2022 | BENZYL ALCOHOL | SUBCONJUNCTIVAL | INJECTION | 0.95 %w/v | MDE Replacement | ||
| Q4 2022 | BENZYL ALCOHOL | SUBCONJUNCTIVAL | INJECTION | 252mg | MDE Replacement | ||
| Q3 2022 | BUTYLATED HYDROXYANISOLE | TOPICAL | GEL | 0.05 %w/w | MDE Replacement | ||
| Q4 2022 | BUTYLATED HYDROXYANISOLE | TOPICAL | GEL | 3mg | MDE Replacement | ||
| Q3 2022 | CALCIUM SILICATE | ORAL | TABLET, ORALLY DISINTEGRATING | 75.00 mg | MDE Replacement | ||
| Q4 2022 | CALCIUM SILICATE | ORAL | TABLET, ORALLY DISINTEGRATING | 600mg | MDE Replacement | ||
| Q3 2022 | CETOSTEARYL ALCOHOL | TOPICAL | CREAM | 12.00 %w/w | MDE Replacement | ||
| Q4 2022 | CETOSTEARYL ALCOHOL | TOPICAL | CREAM | 108mg | MDE Replacement | ||
| Q3 2022 | CETYL ALCOHOL | ORAL | TABLET, EXTENDED RELEASE | 44.00 mg | MDE Replacement | ||
| Q4 2022 | CETYL ALCOHOL | ORAL | TABLET, EXTENDED RELEASE | 132mg | MDE Replacement | ||
| Q3 2022 | CHLOROBUTANOL | INTRAVENOUS | INJECTION | 0.57 %w/v | MDE Replacement | ||
| Q4 2022 | CHLOROBUTANOL | INTRAVENOUS | INJECTION | 25mg | MDE Replacement | ||
| Q3 2022 | CITRIC ACID MONOHYDRATE | INTRAVENOUS | INJECTION, SOLUTION | 5.00 %w/v | MDE Replacement | ||
| Q4 2022 | CITRIC ACID MONOHYDRATE | INTRAVENOUS | INJECTION, SOLUTION | 180mg | MDE Replacement | ||
| Q3 2022 | COCO DIETHANOLAMIDE | TOPICAL | CREAM | 4.00 %w/w | MDE Replacement | ||
| Q4 2022 | COCO DIETHANOLAMIDE | TOPICAL | CREAM | 30mg | MDE Replacement | ||
| Q3 2022 | D&C RED NO. 33 | ORAL | CAPSULE | 0.39 mg | MDE Replacement | ||
| Q4 2022 | D&C RED NO. 33 | ORAL | CAPSULE | 1mg | MDE Replacement | ||
| Q3 2022 | DIMETHYL SULFOXIDE | TOPICAL | SOLUTION | 45.50 %w/w | MDE Replacement | ||
| Q4 2022 | DIMETHYL SULFOXIDE | TOPICAL | SOLUTION | 3640mg | MDE Replacement | ||
| Q3 2022 | DYE GREEN LB-820 | ORAL | TABLET | 0.60 mg | MDE Replacement | ||
| Q4 2022 | DYE GREEN LB-820 | ORAL | TABLET | 2mg | MDE Replacement | ||
| Q3 2022 | EDETATE CALCIUM DISODIUM | INTRAVENOUS | INJECTION | 2.16 mg | MDE Replacement | ||
| Q4 2022 | EDETATE CALCIUM DISODIUM | INTRAVENOUS | INJECTION | 23mg | MDE Replacement | ||
| Q3 2022 | FD&C BLUE NO. 1 | ORAL | CAPSULE, EXTENDED RELEASE | 1.32 mg | MDE Replacement | ||
| Q4 2022 | FD&C BLUE NO. 1 | ORAL | CAPSULE, EXTENDED RELEASE | 1mg | MDE Replacement | ||
| Q3 2022 | FD&C BLUE NO. 2--ALUMINUM LAKE | ORAL | TABLET, ORALLY DISINTEGRATING | 4.70 mg | MDE Replacement | ||
| Q4 2022 | FD&C BLUE NO. 2--ALUMINUM LAKE | ORAL | TABLET, ORALLY DISINTEGRATING | 38mg | MDE Replacement | ||
| Q3 2022 | FD&C GREEN NO. 3 | ORAL | TABLET | 10.00 mg | MDE Replacement | ||
| Q4 2022 | FD&C GREEN NO. 3 | ORAL | TABLET | 240mg | MDE Replacement | ||
| Q3 2022 | FLAVOR RASPBERRY 28106 | ORAL | SUSPENSION/ DROPS | 5.00 mg/ 1.00 ml | MDE Replacement | ||
| Q4 2022 | FLAVOR RASPBERRY 28106 | ORAL | SUSPENSION/ DROPS | 38mg | MDE Replacement | ||
| Q3 2022 | GLYCERIN | ORAL | CONCENTRATE | 750.00 mg/ 1.00 ml | MDE Replacement | ||
| Q4 2022 | GLYCERIN | ORAL | CONCENTRATE | 1800mg | MDE Replacement | ||
| Q3 2022 | GLYCERIN | ORAL | SUSPENSION/ DROPS | 250.00 mg/ 2.50 ml | MDE Replacement | ||
| Q4 2022 | GLYCERIN | ORAL | SUSPENSION/ DROPS | 375mg | MDE Replacement | ||
| Q3 2022 | HEXYLENE GLYCOL | TOPICAL | GEL | 2.00 %w/w | MDE Replacement | ||
| Q4 2022 | HEXYLENE GLYCOL | TOPICAL | GEL | 130mg | MDE Replacement | ||
| Q3 2022 | HIGH DENSITY POLYETHYLENE | TRANSDERMAL | FILM, EXTENDED RELEASE | 85.00 mg | MDE Replacement | ||
| Q4 2022 | HIGH DENSITY POLYETHYLENE | TRANSDERMAL | FILM, EXTENDED RELEASE | 85mg | MDE Replacement | ||
| Q3 2022 | HISTIDINE | INTRAVENOUS | INJECTABLE, LIPOSOMAL | 0.16 %w/v | MDE Replacement | ||
| Q4 2022 | HISTIDINE | INTRAVENOUS | INJECTABLE, LIPOSOMAL | 63mg | MDE Replacement | ||
| Q3 2022 | HYDROCHLORIC ACID | INTRAMUSCULAR | INJECTION, SOLUTION | 1.10 %w/v | MDE Replacement | ||
| Q4 2022 | HYDROCHLORIC ACID | INTRAMUSCULAR | INJECTION, SOLUTION | 8mg | MDE Replacement | ||
| Q3 2022 | HYDROGENATED SOYBEAN PHOSPHATIDYLCHOLINE | INTRAVENOUS | INJECTABLE, LIPOSOMAL | 213.00 mg | MDE Replacement | ||
| Q4 2022 | HYDROGENATED SOYBEAN PHOSPHATIDYLCHOLINE | INTRAVENOUS | INJECTABLE, LIPOSOMAL | 388mg | MDE Replacement | ||
| Q3 2022 | HYDROXYETHYL CELLULOSE (140 MPA.S AT 5%) | ORAL | SOLUTION | 7.50 mg/ 1.00 ml | MDE Replacement | ||
| Q4 2022 | HYDROXYETHYL CELLULOSE (140 MPA.S AT 5%) | ORAL | SOLUTION | 225mg | MDE Replacement | ||
| Q3 2022 | HYDROXYETHYLPIPERAZINE ETHANE SULFONIC ACID | INTRAVENOUS | INJECTION | 0.41 %w/v | MDE Replacement | ||
| Q4 2022 | HYDROXYETHYLPIPERAZINE ETHANE SULFONIC ACID | INTRAVENOUS | INJECTION | 41mg | MDE Replacement | ||
| Q3 2022 | HYDROXYPROPYL CELLULOSE (110000 WAMW) | ORAL | TABLET, EXTENDED RELEASE | 150.00 mg | MDE Replacement | ||
| Q4 2022 | HYDROXYPROPYL CELLULOSE (110000 WAMW) | ORAL | TABLET, EXTENDED RELEASE | 356mg | MDE Replacement | ||
| Q3 2022 | HYPROMELLOSE 2910 (6 MPA.S) | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 16.76 mg | MDE Replacement | ||
| Q4 2022 | HYPROMELLOSE 2910 (6 MPA.S) | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 8mg | MDE Replacement | ||
| Q3 2022 | LACTOSE MONOHYDRATE | VAGINAL | INSERT | 210.00 mg | MDE Replacement | ||
| Q4 2022 | LACTOSE MONOHYDRATE | VAGINAL | INSERT | 630mg | MDE Replacement | ||
| Q3 2022 | LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE | ORAL | TABLET, FILM COATED | 40.00 mg | MDE Replacement | ||
| Q4 2022 | LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE | ORAL | TABLET, FILM COATED | 40mg | MDE Replacement | ||
| Q3 2022 | MAGNESIUM STEARATE | VAGINAL | INSERT | 23.00 mg | MDE Replacement | ||
| Q4 2022 | MAGNESIUM STEARATE | VAGINAL | INSERT | 69mg | MDE Replacement | ||
| Q3 2022 | MANNITOL | SUBCUTANEOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 220.50 mg | MDE Replacement | ||
| Q4 2022 | MANNITOL | SUBCUTANEOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 658mg | MDE Replacement | ||
| Q3 2022 | METHYLPARABEN | ORAL | POWDER, FOR SUSPENSION | 5.00 mg/ 5.00 ml | MDE Replacement | ||
| Q4 2022 | METHYLPARABEN | ORAL | POWDER, FOR SUSPENSION | 5mg | MDE Replacement | ||
| Q3 2022 | MICROCRYSTALLINE CELLULOSE | ORAL | TABLET | 89.60 mg | MDE Replacement | ||
| Q4 2022 | MICROCRYSTALLINE CELLULOSE | ORAL | TABLET | 460mg | MDE Replacement | ||
| Q3 2022 | MONOBASIC POTASSIUM PHOSPHATE | SUBCUTANEOUS | INJECTION | 0.27 %w/v | MDE Replacement | ||
| Q4 2022 | MONOBASIC POTASSIUM PHOSPHATE | SUBCUTANEOUS | INJECTION | 8mg | MDE Replacement | ||
| Q3 2022 | MONOTHIOGLYCEROL | INTRAVENOUS | INJECTION, SOLUTION | 0.01 %w/v | MDE Replacement | ||
| Q4 2022 | MONOTHIOGLYCEROL | INTRAVENOUS | INJECTION, SOLUTION | 158mg | MDE Replacement | ||
| Q4 2022 | OLEYL ALCOHOL | TOPICAL | CREAM | 10.00 %w/w | MDE Replacement | ||
| Q4 2022 | OLEYL ALCOHOL | TOPICAL | CREAM | 20mg | MDE Replacement | ||
| Q3 2022 | OPADRY II 31F58914 WHITE | ORAL | TABLET | 23.00 mg | MDE Replacement | ||
| Q4 2022 | OPADRY II 31F58914 WHITE | ORAL | TABLET | 92mg | MDE Replacement | ||
| Q3 2022 | OPADRY II Y-19-7483 CLEAR | ORAL | CAPSULE, EXTENDED RELEASE | 5.74 mg | MDE Replacement | ||
| Q4 2022 | OPADRY II Y-19-7483 CLEAR | ORAL | CAPSULE, EXTENDED RELEASE | 17mg | MDE Replacement | ||
| Q3 2022 | OPADRY OY-52945 YELLOW | ORAL | TABLET, FILM COATED | 11.95 mg | MDE Replacement | ||
| Q4 2022 | OPADRY OY-52945 YELLOW | ORAL | TABLET, FILM COATED | 24mg | MDE Replacement | ||
| Q3 2022 | OPADRY OY-LS-37200 BUFF | ORAL | TABLET | 10.05 mg | MDE Replacement | ||
| Q4 2022 | OPADRY OY-LS-37200 BUFF | ORAL | TABLET | 10mg | MDE Replacement | ||
| Q3 2022 | OPADRY YS-3-7031 CLEAR | ORAL | TABLET | 17.37 mg | MDE Replacement | ||
| Q4 2022 | OPADRY YS-3-7031 CLEAR | ORAL | TABLET | 69mg | MDE Replacement | ||
| Q3 2022 | PEG-32 HYDROGENATED PALM GLYCERIDES | ORAL | CAPSULE | 12.60 mg | MDE Replacement | ||
| Q4 2022 | STEAROYL POLYOXYL-32 GLYCERIDES | ORAL | CAPSULE | 164mg | MDE Replacement | ||
| Q3 2022 | POLOXAMER 407 | TOPICAL | GEL | 0.20 %w/w | MDE Replacement | ||
| Q4 2022 | POLOXAMER 407 | TOPICAL | GEL | 13mg | MDE Replacement | ||
| Q3 2022 | POLY(DL-LACTIC-CO-GLYCOLIC ACID), (75:25; 20000 MW) | INTRAMUSCULAR | INJECTION, POWDER, FOR SUSPENSION | 3.31 %w/v | MDE Replacement | ||
| Q4 2022 | DL-LACTIDE AND GLYCOLIDE (75:25) COPOLYMER 20000 ACID | INTRAMUSCULAR | INJECTION, POWDER, FOR SUSPENSION | 11mg | MDE Replacement | ||
| Q3 2022 | POLYSORBATE 40 | TOPICAL | GEL | 0.20 %w/w | MDE Replacement | ||
| Q4 2022 | POLYSORBATE 40 | TOPICAL | GEL | 13mg | MDE Replacement | ||
| Q3 2022 | POVIDONE | ORAL | CAPSULE, EXTENDED RELEASE | 72.00 mg | MDE Replacement | ||
| Q4 2022 | POVIDONE | ORAL | CAPSULE, EXTENDED RELEASE | 120mg | MDE Replacement | ||
| Q3 2022 | POVIDONE K25 | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 10.70 mg | MDE Replacement | ||
| Q4 2022 | POVIDONE K25 | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 11mg | MDE Replacement | ||
| Q3 2022 | POVIDONE K30 | ORAL | SOLUTION | 30.50 mg/ 1.00 ml | MDE Replacement | ||
| Q4 2022 | POVIDONE K30 | ORAL | SOLUTION | 90mg | MDE Replacement | ||
| Q3 2022 | POVIDONE K30 | VAGINAL | INSERT | 49.00 mg | MDE Replacement | ||
| Q4 2022 | POVIDONE K30 | VAGINAL | INSERT | 147mg | MDE Replacement | ||
| Q3 2022 | POWDERED CELLULOSE | ORAL | POWDER, FOR SUSPENSION | NA | MDE Replacement | ||
| Q4 2022 | POWDERED CELLULOSE | ORAL | POWDER, FOR SUSPENSION | 1455mg | MDE Replacement | ||
| Q3 2022 | PROPYLENE GLYCOL | ORAL | CAPSULE, LIQUID FILLED | 17.70 mg | MDE Replacement | ||
| Q4 2022 | PROPYLENE GLYCOL | ORAL | CAPSULE, LIQUID FILLED | 42mg | MDE Replacement | ||
| Q3 2022 | PROPYLPARABEN SODIUM | ORAL | POWDER, FOR SUSPENSION | 1.23 mg/ 5.00 ml | MDE Replacement | ||
| Q4 2022 | PROPYLPARABEN SODIUM | ORAL | POWDER, FOR SUSPENSION | 16mg | MDE Replacement | ||
| Q3 2022 | SACCHARIN SODIUM | ORAL | CONCENTRATE | 1.50 mg/ 1.00 ml | MDE Replacement | ||
| Q4 2022 | SACCHARIN SODIUM | ORAL | CONCENTRATE | 6mg | MDE Replacement | ||
| Q3 2022 | SILICON DIOXIDE | VAGINAL | INSERT | 2.50 mg | MDE Replacement | ||
| Q4 2022 | SILICON DIOXIDE | VAGINAL | INSERT | 8mg | MDE Replacement | ||
| Q3 2022 | SIMETHICONE EMULSION | TOPICAL | CREAM | 0.20 %w/w | MDE Replacement | ||
| Q4 2022 | SIMETHICONE EMULSION | TOPICAL | CREAM | 4mg | MDE Replacement | ||
| Q3 2022 | SODIUM ALGINATE | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 320.00 mg | MDE Replacement | ||
| Q4 2022 | SODIUM ALGINATE | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 640mg | MDE Replacement | ||
| Q3 2022 | SODIUM BENZOATE | ORAL | SUSPENSION | 278.70 mg | MDE Replacement | ||
| Q4 2022 | SODIUM BENZOATE | ORAL | SUSPENSION | 37mg | MDE Replacement | ||
| Q3 2022 | SODIUM BENZOATE | ORAL | SUSPENSION/ DROPS | 3.00 mg/ 1.00 ml | MDE Replacement | ||
| Q4 2022 | SODIUM BENZOATE | ORAL | SUSPENSION/ DROPS | 15mg | MDE Replacement | ||
| Q3 2022 | SODIUM BICARBONATE | VAGINAL | INSERT | 43.00 mg | MDE Replacement | ||
| Q4 2022 | SODIUM BICARBONATE | VAGINAL | INSERT | 129mg | MDE Replacement | ||
| Q3 2022 | SODIUM CHLORIDE | INTRAMUSCULAR | INJECTION, SUSPENSION | 0.87 %w/v | MDE Replacement | ||
| Q4 2022 | SODIUM CHLORIDE | INTRAMUSCULAR | INJECTION, SUSPENSION | 26mg | MDE Replacement | ||
| Q3 2022 | SODIUM CHLORIDE | SOFT TISSUE | INJECTION, SUSPENSION | 0.22 %w/v | MDE Replacement | ||
| Q4 2022 | SODIUM CHLORIDE | SOFT TISSUE | INJECTION, SUSPENSION | 26mg | MDE Replacement | ||
| Q3 2022 | SODIUM LAURYL SULFATE | VAGINAL | INSERT | 5.00 mg | MDE Replacement | ||
| Q4 2022 | SODIUM LAURYL SULFATE | VAGINAL | INSERT | 15mg | MDE Replacement | ||
| Q3 2022 | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | ORAL | TABLET | 96.00 mg | MDE Replacement | ||
| Q4 2022 | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | ORAL | TABLET | 96mg | MDE Replacement | ||
| Q3 2022 | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | SUBCUTANEOUS | INJECTION | 0.66 %w/v | MDE Replacement | ||
| Q4 2022 | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | SUBCUTANEOUS | INJECTION | 20mg | MDE Replacement | ||
| Q3 2022 | SORBIC ACID | ORAL | SUSPENSION | 5.00 mg/ 5.00 ml | MDE Replacement | ||
| Q4 2022 | SORBIC ACID | ORAL | SUSPENSION | 22mg | MDE Replacement | ||
| Q3 2022 | STARCH, CORN | VAGINAL | INSERT | 210.00 mg | MDE Replacement | ||
| Q4 2022 | STARCH 1500, PREGELATINIZED | VAGINAL | INSERT | 147mg | MDE Replacement | ||
| Q3 2022 | SUCROSE | ORAL | SUSPENSION/ DROPS | 1250.00 mg/ 2.50 ml | MDE Replacement | ||
| Q4 2022 | SUCROSE | ORAL | SUSPENSION/ DROPS | 2250mg | MDE Replacement | ||
| Q3 2022 | SUCROSE STEARATE | ORAL | CAPSULE, EXTENDED RELEASE | 44.57 mg | MDE Replacement | ||
| Q4 2022 | SUCROSE STEARATE | ORAL | CAPSULE, EXTENDED RELEASE | 57mg | MDE Replacement | ||
| Q3 2022 | XANTHAN GUM | ORAL | SUSPENSION/ DROPS | 2.90 mg/ 1.00 ml | MDE Replacement | ||
| Q4 2022 | XANTHAN GUM | ORAL | SUSPENSION/ DROPS | 15mg | MDE Replacement |
FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections: IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly
Data Through: October 1, 2022
Database Last Updated: October 19, 2022